Navigating the RSV Vaccine Landscape: Which Option is Best for You?
Three new products, including vaccines and drugs, have been developed to prevent respiratory syncytial virus (RSV), a dangerous illness that affects children under 5 and adults over 60. RSV can cause severe illness, hospitalization, and death. Two vaccines, Arexvy and Abrysvo, have been approved for adults 60 and older, as well as for individuals with chronic heart or lung conditions. Abrysvo can also be taken by pregnant women in their third trimester to pass protection to their unborn babies. Additionally, a non-vaccine drug called Beyfortus has been approved for infants, reducing the risk of RSV-related hospitalizations by 80%. However, shortages and financial barriers have limited access to these preventive measures. In the meantime, practicing good hygiene and getting vaccinated for influenza and COVID-19 can help enhance immunity against RSV.